ArticleBMC gastroenterology2025
Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe impact of direct acting antivirals (DAAs) on hepatitis C virus related hepatocellular carcinoma (HCV-HCC) incidence after sustained virologic response (SVR) remains controversial. We aimed to compare long-term HCC incidence after SVR induced by interferon (IFN) and DAA therapy, also to construct a nomogram model for predicting long-term HCC incidence after HCV cure.
methodsA total of 405 patients treated with IFN or DAA were analyzed. 200 patients who achieved SVR were assigned to IFN and DAA group by propensity score matching. The COX regression, LASSO logistic regression, and best subset regression (BSR) were adopted to select variables independently associated with HCC incidence and construct nomogram.
resultsAfter a median follow-up period of 72.0 (interquartile range 57.5–90.0) months, HCC developed in 7 (7%) and 15 (15%) patients in IFN and DAA groups, respectively. The cumulative HCC rates were comparable between the two groups (HR: 0.917, 95% CI: 0.262–1.968, P = 0.520). Out of all three models constructed by COX, LASSO and BSR, model 2 and 3 both contained gender, age, platelet count and alkaline phosphatase, exhibited the minimum Akaike Information Criterion (174.54) and the best predictive performance for 8-year HCC incidence (AUROC = 0.905). Using these four factors, a novel nomogram was established to predict 8-year HCC occurrence following HCV eradication. It showed significant clinical benefit according to decision curve analysis.
conclusionsDAAs exert the same long-term protect role against HCC as IFN treatment, though the development of HCC is still inevitable. Herein, we developed a 8-year HCC-predicting nomogram that can be used to guide clinical screening strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.